These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8794154)

  • 1. Bladder cancer.
    Ozen H
    Curr Opin Oncol; 1996 May; 8(3):259-63. PubMed ID: 8794154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer.
    Bochner BH; Esrig D; Groshen S; Dickinson M; Weidner N; Nichols PW; Skinner DG; Cote RJ
    Clin Cancer Res; 1997 Sep; 3(9):1615-22. PubMed ID: 9815851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bladder carcinoma: understanding advanced and metastatic disease with potential molecular therapeutic targets.
    Ahmed HU; Arya M; Patel HR
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):1011-22. PubMed ID: 16336092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular alterations associated with bladder cancer initiation and progression.
    Cordon-Cardo C
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.
    Friedrich MG; Toma MI; Petri S; Cheng JC; Hammerer P; Erbersdobler A; Huland H
    Eur Urol; 2004 Jun; 45(6):737-43. PubMed ID: 15149745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
    Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
    Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New generation of prognostic factors in muscle invasive bladder cancer.
    Abi-Aad AS
    Acta Urol Belg; 1996 May; 64(2):47-9. PubMed ID: 8701811
    [No Abstract]   [Full Text] [Related]  

  • 9. Two molecular pathways to transitional cell carcinoma of the bladder.
    Spruck CH; Ohneseit PF; Gonzalez-Zulueta M; Esrig D; Miyao N; Tsai YC; Lerner SP; Schmütte C; Yang AS; Cote R
    Cancer Res; 1994 Feb; 54(3):784-8. PubMed ID: 8306342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
    Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
    J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
    Knowles MA
    Carcinogenesis; 2006 Mar; 27(3):361-73. PubMed ID: 16352616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma.
    Zhang ZT; Pak J; Shapiro E; Sun TT; Wu XR
    Cancer Res; 1999 Jul; 59(14):3512-7. PubMed ID: 10416618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bladder cancer.
    Ozen H
    Curr Opin Oncol; 1998 May; 10(3):273-8. PubMed ID: 9619365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and epigenetic aspects of bladder cancer.
    Kim WJ; Quan C
    J Cell Biochem; 2005 May; 95(1):24-33. PubMed ID: 15759278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Urothelial cancers. Cytogenetic and molecular biology principles].
    Strohmeyer T
    Urologe A; 1994 Mar; 33(2):122-7. PubMed ID: 7909968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging.
    Sugano K; Kakizoe T
    Nat Clin Pract Urol; 2006 Dec; 3(12):642-52. PubMed ID: 17149381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.
    Crew JP; O'Brien T; Bradburn M; Fuggle S; Bicknell R; Cranston D; Harris AL
    Cancer Res; 1997 Dec; 57(23):5281-5. PubMed ID: 9393750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A molecular signature in superficial bladder carcinoma predicts clinical outcome.
    Dyrskjøt L; Zieger K; Kruhøffer M; Thykjaer T; Jensen JL; Primdahl H; Aziz N; Marcussen N; Møller K; Orntoft TF
    Clin Cancer Res; 2005 Jun; 11(11):4029-36. PubMed ID: 15930337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bladder cancer: modeling and translation.
    Rosenberg JE; Hahn WC
    Genes Dev; 2009 Mar; 23(6):655-9. PubMed ID: 19299556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.